in this post, u will find 2 links, one is on e product from MERCK where ADO's technology is applied to and the other link is focusing on Roche's diagnostic division and how and how well this sort of products perform and what are the focus in the IVD market by the market leader.
i reckon this is the new product from Merck where ADO's Mix&Go technology is being applied. http://www.estapor.com/estapor//front/blob/bio_estapor_merck.pdf?blobCode=61
this is part from Roche's report, full details can be found here http://finchannel.com/news_flash/Pharmacy/73171_Roche_Group_posts_solid_sales_growth_in_first_nine_months/
Roche?s Diagnostics Division recorded nine-month sales of 7,732 million Swiss francs. Sales grew 8% in local currencies (5% in Swiss francs, 9% in US dollars), once again advancing ahead of the global market. All five business areas increased their sales, with Professional Diagnostics and Diabetes Care the biggest contributors to growth. Major new tests were launched, including a molecular test for detecting methicillin-resistant Staphylococcus aureus, one of the most frequent causes of hospital infections; the first simultaneous test for parvovirus B19 and hepatitis A virus in human plasma; a unique viral-load test to quantify HIV levels even when mutations are present; and a DNA-based tissue test to assess the likelihood of response to treatment with Herceptin in gastric cancer. The latest addition to the cobas 8000 modular analyser series ? a new highthroughput immunoassay module in markets accepting the CE Mark ? and the series? US market entry, will strengthen Roche Diagnostics? position in the high-volume segment of the global clinical laboratory market. Nine-month sales grew ahead of the market in all regions, with the division continuing to record excellent growth in Asia?Pacific and Latin America. In September Roche completed the acquisition of BioImagene Inc., a leader in digital pathology, for approximately 100 million Swiss francs.
Professional Diagnostics? nine-month sales rose 10%, about twice as fast as the market, to 3,602 million Swiss francs. The immunoassay business grew 16%, gaining additional market share due to new placements of cobas analysers as well as strong sales of assays, particularly for cardiac biomarkers. Other key growth drivers were clinical chemistry (5%) and point-of-care solutions (8%). In the US, Professional Diagnostics launched an immunoassay to diagnose hepatitis A infection and five 9-minute STAT-immunoassays for cardiac biomarkers, enabling substantially faster delivery of results to doctors treating heart patients. Following FDA approval in September, the rollout of the cobas 8000 series? clinical chemistry modules c 701 and c 502 commenced in the US. In July the new cobas 8000 immunoassay module e 602 was launched in Europe and countries recognising the CE Mark; US launch is expected later this year. This module, which has a throughput of 170 tests per hour, will drive further testing efficiency gains by enabling large-volume laboratories to fully consolidate their serum work areas.
Diabetes Care?s combined sales of blood glucose monitoring systems and insulin pumps outpaced the market, rising 5%, to 2,191 million Swiss francs. The main growth drivers were the Accu-Chek Aviva/AccuChek Performa blood glucose monitoring systems, both of which posted strong double-digit sales growth, supported by continued strong market uptake of the sleek Accu-Chek Aviva Nano/Accu-Chek Performa Nano meters and the strip-free Accu-Chek Mobile system. The insulin delivery business again posted double-digit sales growth, with Accu-Chek Combo, a combined insulin pump and blood glucose monitoring system, now available in 22 European and Asia-Pacific countries. Diabetes Care announced a technology partnership with eHealth specialist InterComponentWare to develop a global web-based solution that can facilitate efficient and secure data sharing and simplifying communication between diabetes patients and their healthcare providers.
Molecular Diagnostics posted nine-month sales of 900 million Swiss francs, a 4% increase over the yearearlier period. Growth was led by virology and blood screening in Eastern Europe, North America and Asia?Pacific. Strong demand continued for the fully automated cobas 4800 system for mid- to high-throughput laboratories, which is now in use in more than 20 countries in Europe, Latin America and Asia?Pacific. The recently approved tests for methicillin-resistant Staphylococcus aureus (LightCycler MRSA Advanced Test) and HIV (dual PCR-target COBAS AmpliPrep/COBAS TaqMan HIV Test) were successfully launched in the US. In the third quarter Molecular Diagnostics also received regulatory approvals for the cobas TaqScreen DPX Test and the COBAS AmpliPrep/COBAS TaqMan HBV Test. The cobas TaqScreen DPX Test, which received CE Mark certification, is the first duplex test for parvovirus B19 and hepatitis A virus enabling simultaneous real-time detection of both viruses in a single assay, for increased safety of human plasma and plasma products. The COBAS AmpliPrep/COBAS TaqMan HBV Test, a new-generation viral-load test for the management of hepatitis B, which enables broader genotype detection and offers improved workflow flexibility, was approved by the FDA. Data from the ATHENA trial confirming the increased accuracy of human papillomavirus DNA testing using the cobas 4800 HPV test over conventional cytologic Pap testing were presented at the International Papillomavirus Conference in July.
ADO Price at posting:
4.9¢ Sentiment: Buy Disclosure: Held
(20min delay)